(Q37575626)

21 August 2017

1 reference

title

Molecular determinants of tumor recurrence in the urinary bladder (English)

1 reference

21 August 2017

6

Rodolfo Montironi

1 reference

21 August 2017

1

Liang Cheng

1 reference

21 August 2017

Antonio Lopez-Beltran

series ordinal

7

object named as

Antonio Lopez-Beltran

1 reference

21 August 2017

5

Michael O Koch

1 reference

21 August 2017

Shaobo Zhang

2

1 reference

21 August 2017

Darrell D Davidson

series ordinal

3

1 reference

21 August 2017

Gregory T MacLennan

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

843-857

1 reference

Biology and management of bladder cancer

21 August 2017

cites work

1 reference

Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer

21 January 2018

1 reference

Urothelial tumorigenesis: a tale of divergent pathways

21 January 2018

1 reference

Predicting the survival of bladder carcinoma patients treated with radical cystectomy.

21 January 2018

1 reference

Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma.

21 January 2018

1 reference

Implications of cancer stem cells in the treatment of cancer

21 January 2018

1 reference

Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor.

21 January 2018

1 reference

Molecular evidence supporting field effect in urothelial carcinogenesis

21 January 2018

1 reference

Oligoclonality in bladder cancer: the implication for molecular therapies

21 January 2018

1 reference

TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder.

21 January 2018

1 reference

Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells

21 January 2018

1 reference

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors

21 January 2018

1 reference

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

21 January 2018

1 reference

OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer

21 January 2018

1 reference

Identification of side population cells from bladder cancer cells by DyeCycle Violet staining

21 January 2018

1 reference

Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance

21 January 2018

1 reference

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma

21 January 2018

1 reference

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

21 January 2018

1 reference

Methylation and repeats in silent and nonsense mutations of p53.

21 January 2018

1 reference

Carcinogen exposure and gene promoter hypermethylation in bladder cancer

21 January 2018

1 reference

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

21 January 2018

1 reference

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

21 January 2018

1 reference

Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction

21 January 2018

1 reference

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

21 January 2018

1 reference

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer

21 January 2018

1 reference

Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.

21 January 2018

1 reference

Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype

21 January 2018

1 reference

Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain

21 January 2018

1 reference

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

21 January 2018

1 reference

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

21 January 2018

1 reference

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

21 January 2018

1 reference

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target

21 January 2018

1 reference

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

21 January 2018

1 reference

Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur

21 January 2018

1 reference

Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract.

21 January 2018

1 reference

FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations.

21 January 2018

1 reference

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma

21 January 2018

1 reference

p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer

21 January 2018

1 reference

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

21 January 2018

1 reference

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

21 January 2018

1 reference

Identifying distinct classes of bladder carcinoma using microarrays.

21 January 2018

1 reference

P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.

21 January 2018

1 reference

Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.

21 January 2018

1 reference

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles

21 January 2018

1 reference

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

21 January 2018

1 reference

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

21 January 2018

1 reference

Genetic and epigenetic aspects of bladder cancer

21 January 2018

1 reference

Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.

21 January 2018

1 reference

Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.

21 January 2018

1 reference

Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence.

21 January 2018

1 reference

Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium

21 January 2018

1 reference

The random development of LOH on chromosome 9q in superficial bladder cancers.

21 January 2018

1 reference

Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer

21 January 2018

1 reference

Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder

21 January 2018

1 reference

Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer

21 January 2018

1 reference

Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.

21 January 2018

1 reference

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

21 January 2018

1 reference

The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.50

1 reference

21 August 2017

1 reference